As of Friday close, Poseida Therapeutics Inc.’s (NASDAQ:PSTX) stock was down -$0.16, moving down -6.08 percent to $2.47. The average number of shares traded per day over the past five days has been 603,660 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.32 fall in that time frame. In the last twenty days, the average volume was 1,518,210, while in the previous 50 days, it was 1,361,374.
Since last month, PSTX stock rose 27.98%. Shares of the company fell to $1.60 on 08/04/23, the lowest level in the past month. A 52-week high of $8.82 was reached on 02/08/23 after having rallying from a 52-week low of $1.54. Since the beginning of this year, PSTX’s stock price has dropped by -53.40% or -$2.83, and marked a new high 13 times. However, the stock has declined by -72.00% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
The stock’s beta is -0.20. Besides these, the trailing price-to-sales (P/S) ratio of 1.62, the price-to-book (PB) ratio of 1.58.
Financial Health
In the three months ended June 29, Poseida Therapeutics Inc.’s quick ratio stood at 4.60, while its current ratio was 4.60, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.43, and the total debt-to-equity ratio was 0.43. In the year ended June 29, EBITDA margin amounted to -82.44%, whereas operating margins totaled -20.70%. Based on annual data, PSTX earned $190.44 million in gross profit and brought in $130.49 million in revenue.
In Poseida Therapeutics Inc.’s quarter-end financial report for June 29, it reported total debt of $58.4 million against cash and short-term investments of $164.7 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. PSTX’s revenue rose 86.51% to $10.34 million during the quarter, while net income inched up to $20.01 million. While analysts expected Poseida Therapeutics Inc. to report -$0.53 quarterly earnings, the actual figure was -$0.32 per share, beating the consensus estimate by 39.60%. During the quarter, the company generated -$28.36 million in EBITDA. The liabilities of Poseida Therapeutics Inc. were 145.91 million at the end of its most recent quarter ended June 29, and its total debt was $87.08 million. The value of shareholders’ equity is $86.92 million.
Technical Picture
This quick technical analysis looks at Poseida Therapeutics Inc.’s (PSTX) price momentum. With a historical volatility rate of 174.16%, the RSI 9-day stood at 58.89% on 18 August.
With respect to its five-day moving average, the current Poseida Therapeutics Inc. price is down by -11.47% percent or -$0.32. At present, PSTX shares trade +26.67% above its 20-day simple moving average and -26.71% percent below its 100-day simple moving average. However, the stock is currently trading approximately +3.78% above its SMA50 and -39.76% below its SMA200.
Stochastic coefficient K was 67.38% and Stochastic coefficient D was 68.41%, while ATR was 0.27. Given the Stochastic reading of 61.92% for the 14-day period, the RSI (14) reading has been calculated as 58.68%. As of today, the MACD Oscillator reading stands at -0.01, while the 14-day reading stands at 0.29.
Analyst Ratings
H.C. Wainwright launched its rating on Poseida Therapeutics Inc. (NASDAQ: PSTX) to a Buy in a note to investors on January 04, 2023. Poseida Therapeutics Inc. (PSTX) has been rated Buy by analysts. According to 0 brokerage firms, PSTX is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Poseida Therapeutics Inc. stock as buy, with 6 recommending it as overweight.
With a median target price of $12.00, the current consensus forecast for the stock is $8.00 – $15.00. Based on these forecasts, analysts predict Poseida Therapeutics Inc. (PSTX) will achieve an average price target of $11.80.
